These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 29431526)

  • 1. The potential role of statins in treating liver disease.
    Imprialos KP; Stavropoulos K; Doumas M; Skalkou A; Zografou I; Athyros VG
    Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):331-339. PubMed ID: 29431526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins.
    Ratchford EV; Martin SS
    Vasc Med; 2017 Oct; 22(5):442-445. PubMed ID: 28803537
    [No Abstract]   [Full Text] [Related]  

  • 4. Under-prescription of statins in patients with non-alcoholic fatty liver disease.
    Del Ben M; Baratta F; Polimeni L; Pastori D; Loffredo L; Averna M; Violi F; Angelico F
    Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):161-167. PubMed ID: 27914698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease.
    Doumas M; Imprialos K; Dimakopoulou A; Stavropoulos K; Binas A; Athyros VG
    Curr Pharm Des; 2018; 24(38):4587-4592. PubMed ID: 30652643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins: Are they really all the same?
    Cortese F
    Curr Vasc Pharmacol; 2019; 17(3):211-212. PubMed ID: 30003860
    [No Abstract]   [Full Text] [Related]  

  • 7. Exploring the Management of Statin Intolerant Patients: 2016 and Beyond.
    Katsiki N; Athyros VG; Karagiannis A
    Curr Vasc Pharmacol; 2016; 14(6):523-533. PubMed ID: 26916398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to Overcome Residual Risk During Statins Era.
    Cho KI; Yu J; Hayashi T; Han SH; Koh KK
    Circ J; 2019 Sep; 83(10):1973-1979. PubMed ID: 31391351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials.
    Naci H; Brugts J; Ades T
    Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):390-9. PubMed ID: 23838105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins and the liver.
    Herrick C; Bahrainy S; Gill EA
    Cardiol Clin; 2015 May; 33(2):257-65. PubMed ID: 25939298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging views of statin pleiotropy and cholesterol lowering.
    Yu D; Liao JK
    Cardiovasc Res; 2022 Jan; 118(2):413-423. PubMed ID: 33533892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to improve statin prescription guidelines in low-risk patients?
    Balder JW; de Vries JK; Mulder DJ; Kamphuisen PW
    Eur J Prev Cardiol; 2017 Jul; 24(10):1064-1070. PubMed ID: 28429651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease and statins.
    Tziomalos K; Athyros VG; Paschos P; Karagiannis A
    Metabolism; 2015 Oct; 64(10):1215-23. PubMed ID: 26234727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease.
    Pastori D; Polimeni L; Baratta F; Pani A; Del Ben M; Angelico F
    Dig Liver Dis; 2015 Jan; 47(1):4-11. PubMed ID: 25224698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of statin therapy.
    Adhyaru BB; Jacobson TA
    Nat Rev Cardiol; 2018 Dec; 15(12):757-769. PubMed ID: 30375494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin use in patients with elevated serum hepatic transaminases at baseline: A meta-analysis.
    Masson W; Lobo M; Masson G; Molinero G; Casciato P
    Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1357-1364. PubMed ID: 33715945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonadherence to statins: individualized intervention strategies outside the pill box.
    Lansberg P; Lee A; Lee ZV; Subramaniam K; Setia S
    Vasc Health Risk Manag; 2018; 14():91-102. PubMed ID: 29872306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits.
    Anfossi G; Massucco P; Bonomo K; Trovati M
    Nutr Metab Cardiovasc Dis; 2004 Aug; 14(4):215-24. PubMed ID: 15553600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of fenofibrate in clinical practice.
    Zambon A; Cusi K
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges.
    Ahmed MH; Al-Atta A; Hamad MA
    Expert Opin Pharmacother; 2012 Sep; 13(13):1901-9. PubMed ID: 22770622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.